Pharmacy considerations

Pharmacy considerations

Pharmacy considerations

Back to all clinical trials sub-sections
pdf
16/11/2020

Cellular ATMP cryopreserved allogeneic example receipt checklist

This document sets out an example generic checklist for allogeneic, cryopreserved, cellular Advanced Therapy Medicinal Products (ATMPs).
Open PDF
pdf
18/11/2020

Cellular ATMP cryopreserved autologous example receipt checklist

This document sets out an example generic checklist for autologous, cryopreserved, cellular Advanced Therapy Medicinal Products (ATMPs)
Open PDF
pdf
18/11/2020

Cellular ATMP fresh allogeneic example receipt checklist

This document sets out an example generic checklist for receipt and storage of fresh, allogeneic, cellular Advanced Therapy Medicinal Products
Open PDF
pdf
19/10/2021

Cellular ATMP fresh autologous example receipt checklist

This document sets out an example generic checklist for receipt and storage of fresh, autologous, cellular Advanced Therapy Medicinal Products.
Open PDF
pdf
11/06/2021

Checklist for receipt of empty shipper

Form to complete when receiving, processing and releasing fresh cells for manufacturing
Open PDF
pdf
15/09/2021

Checklist for receipt of frozen product

A checklist to confirm ATMP is received appropriately from the manufacturer prior to administration to a patient
Open PDF
pdf
18/10/2021

Competency Assessment: Safe use of dry shippers and/or dry ice

This document can be used to help prompt consideration and recording of the competencies that are needed to work safely with dry shippers and/or dry ice.
Open PDF
Online Article
12/07/2022

Costing Clinical Trials of ATiMPs using the NIHR interactive Costing Tool – Advice for Pharmacy Sites

Advice produced by the Pan UK Pharmacy Working Group for ATMPs for Pharmacy sites on costings for clinical trials of ATMPs, using the NIHR interactive costing tool.
Go to link
Online Article
04/12/2020

Diagnosis and medical management of acute CAR-T cell toxicities in adults

This document produced by the Pan UK Pharmacy Working Group for ATMPs provides guidance on the management of acute CAR-T cell toxicities to help inform the development of local guidelines and to standardise the management of acute CAR-T cell toxicities across the UK. This is a consensus guideline developed with input from the pharmacists and consultants from the first and second wave CAR-T centres.
Go to link
pdf
16/11/2021

Disposal of IMP or ATMP Product

Form to be completed on the disposal of IMP or ATMP
Open PDF
Online Article
21/07/2020

Ex Vivo (cell based) gene therapy medicinal products – pharmacy institutional readiness guidance

Ex vivo gene therapy medicinal products are ATMPs, which require pharmacy oversight, even when being handled elsewhere within a healthcare organisation. This document produced by the Pan UK Pharmacy Working Group for ATMPs outlines the key areas where chief pharmacists should focus pharmaceutical expertise prior to an organisation implementing any ex vivo (cell based) Gene Therapy Medicinal Product (GTMP)
Go to link
pdf

Example risk assessment for proposed activities involving; Gene Therapy Medicinal Products (GTMPs) or Gene Therapy Investigational Medicinal Products (GTIMPs)

An example risk assessment used to fully review the risk posed by GTMP/GTiMPs in preparation for submission to local genetic modification safety committee
Open PDF
pdf
22/09/2022

Feasibility and risk assessment for all clinical trials

Template for the feasibility and risk assessment of all clinical trials (not just ATIMP)
Open PDF
Online Article
30/10/2019

Gene Therapy Medicinal Products – Governance and Preparation Requirements

A Pharmacy Working Group for ATMPs resource. Pharmacy is often the first port of call when an organisation wishes to use a gene therapy and needs to provide pragmatic guidance to facilitate the introduction of these innovative products. This document is designed to give practical advice to centres wishing to undertake gene therapy trials and need to understand the requirements and recommendations for governance and, in particular to have in place a Genetic Modification Safety Committee. The document also gives practical advice for centres to help them understand operational requirements including deciding the optimal location for preparation.
Go to link
Online Article
01/01/2020

Guidance on Pharmacy oversight and Pharmacist Supervision of licensed ATMPs requiring a preparation/reconstitution step

Guidance produced by the Pan UK Pharmacy Working Group for ATMPs, providing definitions of oversight and supervision and clarifies where each are required when implementing Advanced Therapy Medicinal Products
Go to link

Explore all clinical trials sub-sections

  • Advanced therapy clinical trials process overview

    Advanced therapy clinical trials process overview

    Read more about this section.

    This section features The NIHR Clinical Trials Toolkit and The ABPI ATMP road map

    View resources
  • Trial Governance

    Trial Governance

    Read more about this section.

    Information regarding the governance arrangements required within the NHS to approve, set up and manage clinical trials of advanced therapy investigational products is included here, with details on local governance, committees, feasibility and risk assessments.

    View resources
  • Procurement of Starting Materials

    Procurement of Starting Materials

    Read more about this section.

    Information and considerations during the collection of starting materials for the manufacture of advanced therapies can be found here, including model SOPs in relation to:

    • Solid tumours A suite of SOPS by cancer type relating to sample collection for isolation of tumour-infiltrating lymphocytes (Tils)
    • Blood (aphaeresis) A suite of SOPS for adoptive cellular therapy (Immune Effector Cells)

    View resources
  • Receipt, storage & issue of advanced therapies

    Receipt, storage & issue of advanced therapies

    Read more about this section.

    Available here are examples of checklists and templates for the safe receipt, storage and issue of advanced therapies within the NHS.

    View resources
  • Pharmacy considerations

    Pharmacy considerations

    Read more about this section.

    The considerations for hospital pharmacy departments delivering advanced therapies, including:

    View resources
  • Clinical management of patients at site

    Clinical management of patients at site

    Read more about this section.

    Includes exemplar SOPs and information regarding the clinical management of patients receiving advanced therapies in a hospital setting, covering patient consent, treatment, management of toxicities and follow-up care.

    View resources
  • Education and training

    Education and training

    Read more about this section.

    This section includes links to webinars, e-learning modules and a range of resources, to assist all staff delivering advanced therapy trials in an NHS setting.

    View resources
  • Performance management and metrics

    Performance management and metrics

    Read more about this section.

    An outline of the barriers to effective advanced therapy clinical trial set up, changes to overcome these barriers, and the key metrics to measure success in terms of trial set up and patient referral and recruitment is available here.

    View resources
  • National infrastructure, templates and guidance

    National infrastructure, templates and guidance

    Read more about this section.

    Links to information on the national infrastructure surrounding the clinical trial application process, also further guidance, and templates to assist in the set up and delivery of advanced therapy clinical trials. Including examples of model ATiMP clinical trial agreements.

    View resources

    • Explore all toolkit sections

  • Governance

    Governance

    Read more about this section.

    This section is intended to assist NHS organisations to create or modify governance structures to permit the introduction of advanced therapies, encompassing all levels of governance responsibilities and reporting within hospitals.

    View resources
  • Business and financial planning

    Business and financial planning

    Read more about this section.

    The introduction of advanced therapies into hospital treatment pathways requires a significant financial investment in resources and facilities. Information available here will help organisations to develop the appropriate business and financial plans as they prepare to deliver advanced therapies.

    View resources
  • Quality assurance and risk management

    Quality assurance and risk management

    Read more about this section.

    This section provides examples of, and guidance on, the implementation of quality systems and risk assessments for safe delivery of advanced therapies towards preparing for regulatory inspections.

    View resources
  • Operational delivery

    Operational delivery

    Read more about this section.

    The documents in this section will assist in the implementation of new advanced therapy services in a clinical setting, supporting the transition of guidance into practice.  Documents include process and patient flow charts to map the treatment pathway and information on the in-hospital logistics requirements.

    View resources
  • Clinical practice

    Clinical practice

    Read more about this section.

    Information is available here to support the clinical practice of the delivery of advanced therapies to patients, including patient assessment, handling advanced therapies, product administration, infusion, treatment and monitoring and recording treatment and side-effects.

    View resources
  • Education and training resources

    Education and training resources

    Read more about this section.

    To safely deliver advanced therapies to patients, staff need to be trained in this new modality of therapeutic intervention. This section includes resources that enable staff to learn more about ATMPs including e-learning, facilitating face to face training and competency assessments, and materials to support patient education.

    View resources
  • Long term follow up

    Long term follow up

    Read more about this section.

    A regulatory feature of advanced therapies is the need for longer-term follow up than for other therapeutic modalities.  The information provided here speaks to the methods of data collection for extended follow up patients after treatment.

    View resources
  • Clinical trials

    Clinical trials

    Read more about this section.

    This section has a range of resources – split into 8 sub-sections – which will assist NHS sites to prepare for the set up and delivery of advanced therapy clinical trials. Its objective is to disseminate learnings from the ATTCs regarding the governance, infrastructure and processes which underpin successful trial set up and delivery.

    View resources